Efficacy and Toxicity of Adjuvant Therapies for High-Risk Endometrial Cancer in Stage I–III: A Systematic Review and Network Meta-Analysis

20 September 2020: Meta-Analysis

Mengyin Ao ^12ABCDEF , Ting Ding ^12BF , Dan Tang ^12E , Mingrong Xi ^12E*

DOI: 10.12659/MSM.925595

Med Sci Monit 2020; 26:e925595

Table 1 Characteristics of included randomized clinical trials.

Author	Sub-category	Location	FIGO stage	Intervention		Sample size			Age, years median (range)
Author	Sub-category	Location	FIGO stage	T1	T2	T1	T2	Total	T1	T2
Randall et al.	GOG-249	USA	I–II	A	B	301	300	601	63 (NR)	65 (NR)
Hogberg et al. (1)	NSGO-RORTC	Sweden	I–IIIC	A	C	191	187	378	64 (44–79)	64 (38–83)
Hogberg et al. (2)	Mango	Sweden	II–III	A	C	76	80	156	59 (42–78)	58 (39–77)
Morrow et al.	GOG-34	USA	I–II occult	A	C	89	92	181	NR	NR
Kuoppala et al.	NR	Finland	I–IIIA	A	C	72	84	156	74 (47–86)	73 (47–85)
de Boer et al.	PORTEC-3	France, Italy, Canada	I–III	A	C	330	330	660	62 (NR)	62 (NR)
Creutzberg et al.	PORTEC-1	Netherlands	I–IIIC	A	D	354	360	714	66 (41–85)	66 (43–90)
Keys et al.	GOG-99	USA	I–II occult	A	D	190	202	392	63 (NR)	63 (NR)
Blake et al.	ASTEC/EN5	UK, Canada, Poland	I–IIB	A	D	452	453	905	65 (36–88)	66 (31–88)
Susumu et al.	JGOG	Japan	IC–IIIC	A	E	193	192	385	NR	NR
Maggi et al.	NR	Italy	IC–IIIC	A	E	166	174	340	62 (NR)	63 (NR)
Sorbe et al.	NR	Sweden	IA–IC	F	G	264	263	527	NR	NR
Sunil et al.	NR	India	IA–IB	F	G	25	25	50	NR	NR
Nout et al.	PORTEC-2	Dutch	IB–IIA	A	G	214	213	427	69 (NR)	70 (NR)
A – pelvic radiotherapy; B – vaginal cuff brachytherapy and chemotherapy; C – pelvic radiotherapy and chemotherapy; D – No further treatment; E – chemotherapy; F – pelvic radiotherapy and vaginal brachytherapy; G – vaginal brachytherapy. ^a Based on FIGO 2009 classification; ^b based on FIGO 1988 classification; ^c based on FIGO 2009 classification; NR – not reported.